Wave Life Sciences
Update in progressWVE (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Wave Life Sciences is a clinical-stage biotech company designing RNA medicines with its PRISM platform, blending modalities, chemistry innovation, and human-genetics insights to treat rare and common diseases. It advances WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 for obesity, WVE-008 for liver disease, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease. Partners include GSK, Takeda, and Asuragen. Founded 2012, Singapore.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Paul B. Bolno M.B.A., M.D.
- Founded2012
- Employees317
- Websitewavelifesciences.com
Identifiers
- ISINSG9999014716
- FIGIBBG00B642V54
- CUSIPY95308105
- CIK0001631574